Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveUnderstanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Our 2015 approach to invasive pulmonary aspergillosis.Dosing of antifungal agents in obese people.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection.No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.
P2860
Q27009221-DC46AE3C-E48D-4AF9-86D3-2594B1D43DB1Q34596750-5D24C47C-197B-4E5C-B816-DC506144D3D8Q37203849-837E5212-D9F9-467E-A682-372ACF3FB513Q38122347-651844B2-5894-462B-A2A0-9CABE5FBCB34Q38140015-93B3CC06-50C3-4246-A353-8586F0A82490Q38284468-2FF02CE6-831F-4F1B-8A14-5767D9599377Q38391049-3617FF3A-9D20-4FFA-8854-920E2B69C45AQ38660761-5294D3D0-2416-417B-A5DF-63032D9EF962Q40517272-587A9512-ADE0-47CA-9686-6BD1DAAD536BQ40841377-72736922-F1F6-4FA0-A4C3-EF022CA55101Q41284722-10F09940-531D-485B-A91D-94648630B4E6Q41291872-0BE17FC1-F7A2-40A6-A030-BB08843C96DEQ44968373-62F0F292-9AC9-4481-9B37-AB7F2B679E33Q52777337-15BE6BA9-61E5-4482-850A-DB174282BC31Q53094227-1B091B55-6BA2-44C3-8925-808591D30175
P2860
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Factors influencing the pharma ...... a or myelodysplastic syndrome.
@en
type
label
Factors influencing the pharma ...... a or myelodysplastic syndrome.
@en
prefLabel
Factors influencing the pharma ...... a or myelodysplastic syndrome.
@en
P2093
P2860
P1476
Factors influencing the pharma ...... a or myelodysplastic syndrome.
@en
P2093
F Farowski
J J Vehreschild
K-A Kreuzer
M J G T Vehreschild
O A Cornely
P2860
P2888
P304
P356
10.1007/S00228-012-1212-Y
P577
2012-06-01T00:00:00Z